Safety, efficacy and dosing of enteral L‐citrulline supplementation in preterm infants. A randomized controlled trial.
Primary Author: Mohammad Qasim Mehdi, MD Mentor: Sunil Jain, MD Background Citrulline (CIT) is a semi-essential amino acid in preterm infants (PI). Through enzymatic reactions in the urea cycle, CIT is converted to arginine (ARG) and serves as a precursor for endogenous synthesis of nitric oxide (NO), a known potent vasodilator that regulates blood supply to the lungs, intestines and other organs. Lower levels of ARG and CIT have been reported in infants with NEC, bronchopulmonary dysplasia associated pulmonary hypertension (BPD-PH) and sepsis. We hypothesized that that enteral CIT supplementation is safe in PI and increases plasma CIT and ARG levels in PI. We speculate that the higher plasma ARG levels in turn will result in increased endogenous NO production, conferring potential benefits in BPD-PH and NEC. Methods A pilot, double blinded, randomized controlled trial (NCT03649932) of 42 PI (< 33 weeks) was conducted. Subjects were randomized to receive low, medium and high dose C...